Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Sacubitril/Valsartan in Healthy Thai Subjects
NCT06273254Phase 1Not yet recruiting
- Sponsor
- Viatris
- Start
- Apr 2024
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of sacubitril + valsartan in heart failure (HF) (2 arms), sponsored by Viatris. Primary endpoints: Maximum Plasma Concentration at 4 months and Area Under the Curve at 4 months. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
sacubitril + valsartan
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT06273254.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06273254.